Dr. Roch Doliveux has extensive leadership experience in biopharmaceuticals, having held both executive and non-executive positions across various companies.

Between 1990 and 2003 Dr Doliveux held various roles at Schering-Plough (now Merck Inc.) successively as General Manager in Belgium and Luxembourg, Vice President and General Manager France, Senior Vice President Managed Care US and President International.

In 2003 Doliveux was named as Chief Executive Officer of Pharmaceuticals at Pierre Fabre.

Between 2003 and 2014, Dr Doliveux held various roles at UCB, first as Director General of Pharmaceuticals and then Chief Executive Officer as of 2004. Between 2010 and 2014, he was also member of the Board and then Chair of IMI, the largest public private partnership in the world for Biopharmaceutical Research.

Subsequently, he held various non-executive directorships, including serving as member of the Board of UCB, Chair of Remuneration Committee of the Board of Stryker (USA) and Chair of the Board for the Pierre Fabre Group since 2017. Since June 2020, he has been the Chair of the Board at Oxford Biomedica, a company specializing in the development and manufacture of viral vectors for cell and gene therapies.

Dr Doliveux received his PhD in Veterinary Medicine with honors from École Nationale Vétérinaire d'Alfort, France in 1980. In 1981, he received an MBA from INSEAD with distinction.

He was bestowed the title of Commander of the Order of the Crown by the Belgian Government in November 2015. Dr Doliveux is a Swiss national.